Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Why Gilead Scinces Stock Tumbled on Tuesday
05:22pm, Tuesday, 10'th Jun 2025
On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (GILD -2.54%) took some hits on Tuesday. Investors traded it down by more than 2%,
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
01:15pm, Tuesday, 10'th Jun 2025
Gilead Sciences, Inc. (NASDAQ:GILD ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ET Company Participants Daniel P. O'Day - Chairman & CEO Conference Call Participants
Gilead shares fall after FDA places clinical hold on HIV treatment trials
10:29am, Tuesday, 10'th Jun 2025
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) dropped up to 4% on Tuesday following an announcement that the US Food and Drug Administration (FDA) has placed clinical holds on studies involving two of th
US FDA places clinical hold on 2 Gilead trials of weekly HIV pill combination
10:03am, Tuesday, 10'th Jun 2025
(Reuters) -The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of its experimental HIV treatments, the company said on Tuesday. (Re
US FDA places clinical hold on 2 Gilead trials of weekly HIV pill combination
10:02am, Tuesday, 10'th Jun 2025
The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of its experimental HIV treatments, the company said on Tuesday.
Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug
01:09pm, Thursday, 05'th Jun 2025
In February, the U.S. Food and Drug Administration (FDA) accepted Gilead Sciences, Inc.'s GILD New Drug Application (NDA) submissions for lenacapavir — the company's twice-yearly injectable HIV-1 ca
Gilead Sciences, Inc. (GILD) Jefferies Global Healthcare Conference (Transcript)
03:19pm, Wednesday, 04'th Jun 2025
Gilead Sciences, Inc. (NASDAQ:GILD ) Jefferies Global Healthcare Conference June 4, 2025 11:05 PM ET Company Participants Cindy Perettie - Executive Vice President of Kite Dietmar P. Berger - Chief Me
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
03:34pm, Tuesday, 03'rd Jun 2025
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.
Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study
10:41am, Monday, 02'nd Jun 2025
GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard care.
Put Cash To Work: 2 Magnificent Dividends I'm Betting On
10:00am, Monday, 02'nd Jun 2025
High-quality assets like RTX and AbbVie are ideal for growth and income, offering inflation resilience and strong shareholder returns. RTX has a robust $217B backlog, rising global defense spending, r
Gilead's CAR-T cell therapy shows promise in deadly brain cancer
08:03am, Sunday, 01'st Jun 2025
A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain cancer with few treatment opti
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced real-world data evaluating the safety and effectiveness of Yescarta® (axicabtagene ciloleucel) for patien
Potentially Earn 12%-15% Income: Monthly Options Series (June 2025)
08:30am, Saturday, 31'st May 2025
We explain why selling cash-covered puts and covered calls is a relatively safe choice for earning high income. We will discuss how to formulate a sustainable and repeatable income strategy for option
Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial
08:13am, Saturday, 31'st May 2025
Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, acc
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) reduced the risk of disease progressi
